This study is testing a new gene therapy called YAP101 for adults with heart failure caused by a previous heart attack (ischemic heart failure) and a weakened pumping ability (reduced ejection fraction). YAP101 aims to help the heart repair itself by delivering a special gene therapy directly to heart cells. Researchers want to see if YAP101 is safe and how well it's tolerated, as well as its early effects on heart function. You might be able to join if you are between 18 and 79 years old, have stable heart failure from a heart attack, and your heart's pumping ability (ejection fraction) is between 20% and 40%. This study is currently recruiting about 24 participants.

Study design

This is a Phase I, single-center, open-label study, meaning everyone knows what treatment is being given. It will enroll about 24 participants to test different doses of YAP101.

What's involved

You would receive a one-time injection of YAP101 into your heart. After that, you would have outpatient visits for monitoring over 12 months.

Compensation

Not stated in the trial record.

Follow-up

Participants will be monitored for safety and other outcomes for 12 months after receiving the treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.